SECURITY AGREEMENT Dated as of February 14, 2022 among AgeX Therapeutics, Inc. and Each Other Grantor From Time to Time Party Hereto and Juvenescence Limited as Agent and Initial LenderSecurity Agreement • February 15th, 2022 • AgeX Therapeutics, Inc. • Pharmaceutical preparations • New York
SECURITY AGREEMENT, dated as of February 14, 2022, by AgeX Therapeutics, Inc., a Delaware corporation, (the “Borrower”) and each of the other entities that becomes a party hereto, including pursuant to Section 8.6 (together with the Borrower, the “Grantors” and each a “Grantor”), in favor of Juvenescence Limited, a company incorporated in the Isle of Man (the “Initial Lender”), in its capacity as the Lender under the Note referred to below and as agent for itself and any other lender under the Note (in such capacity, together with its successors and permitted assigns, “Agent” and the Agent and the Lenders from time to time under the Note, together with their respective successors and permitted assigns, the “Secured Parties”).
Warrant Agreement Dated as of February 14, 2022Warrant Agreement • February 15th, 2022 • AgeX Therapeutics, Inc. • Pharmaceutical preparations • Delaware
WARRANT AGREEMENT (this “Agreement”), dated as of February 14, 2022, by AgeX Therapeutics, Inc., a Delaware corporation (the “Company”), for the benefit of Juvenescence Limited which, along with any permitted successor Holder of a Warrant, is referred to herein as a “Lender”.
AMENDMENT NO. 3 TO REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • February 15th, 2022 • AgeX Therapeutics, Inc. • Pharmaceutical preparations • California
This Amendment No. 3, dated as of February 14, 2022 (the “Amendment”), is entered into by and between AgeX Therapeutics, Inc., a California corporation (the “Company”) and Juvenescence, Limited, a company incorporated in the Isle of Man (the “Holder”). Capitalized terms used in this Amendment and not otherwise defined herein shall have the meanings ascribed thereto in the Registration Rights Agreement (as defined below).
AGEX THERAPEUTICS, INC. COMMON STOCK PURCHASE WARRANTSAgeX Therapeutics, Inc. • February 15th, 2022 • Pharmaceutical preparations
This certifies that, for value received, or its registered assigns (the “Holder”), is entitled to purchase from AgeX Therapeutics, Inc., a Delaware corporation (the “Company”), at a purchase price per share of [ ] Dollars and [ ] cents ($[ ]) (the “Warrant Price”), [________________(________)] shares of its Common Stock, par value $0.0001 per share (the “Common Stock”). The number of shares purchasable upon exercise of the Common Stock Purchase Warrants (the “Warrants”) and the Warrant Price are subject to adjustment from time to time as set forth in the Warrant Agreement referred to below. Outstanding Warrants not exercised prior to 5:00 p.m., New York time, on the third anniversary of the original issue date hereof (the “Expiration Date”) shall thereafter be void.
